162 related articles for article (PubMed ID: 9915275)
1. Pharmacokinetics of intermittent intraperitoneal ceftazidime.
Grabe DW; Bailie GR; Eisele G; Frye RF
Am J Kidney Dis; 1999 Jan; 33(1):111-7. PubMed ID: 9915275
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of intermittent intraperitoneal cefazolin in continuous ambulatory peritoneal dialysis patients.
Manley HJ; Bailie GR; Asher RD; Eisele G; Frye RF
Perit Dial Int; 1999; 19(1):65-70. PubMed ID: 10201343
[TBL] [Abstract][Full Text] [Related]
3. Disposition of ceftazidime after intraperitoneal administration in adolescent patients receiving continuous cycling peritoneal dialysis.
Sisterhen LL; Stowe CD; Farrar HC; Blaszak CK; Blaszak RT
Am J Kidney Dis; 2006 Mar; 47(3):503-8. PubMed ID: 16490630
[TBL] [Abstract][Full Text] [Related]
4. Short-Dwell Cycling Intraperitoneal Cefazolin Plus Ceftazidime in Peritoneal Dialysis Patients.
Peerapornratana S; Chariyavilaskul P; Kanjanabuch T; Praditpornsilpa K; Eiam-Ong S; Katavetin P
Perit Dial Int; 2017; 37(2):218-224. PubMed ID: 27738089
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic analysis of ceftazidime and cefazolin in the treatment of continuous ambulatory peritoneal dialysis-related peritonitis.
Zhu W; Fang X; Zheng J; Ke Y; He Q; Cui T; Chen B; Tian L
Ren Fail; 2023; 45(2):2285873. PubMed ID: 38044852
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of once daily intraperitoneal cefazolin in continuous ambulatory peritoneal dialysis patients.
Low CL; Gopalakrishna K; Lye WC
J Am Soc Nephrol; 2000 Jun; 11(6):1117-1121. PubMed ID: 10820176
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of intraperitoneal cefazolin and ceftazidime coadministered to CAPD patients.
Elwell RJ; Manley HJ; Frye RF; Bailie GR
Int J Artif Organs; 2005 Aug; 28(8):808-16. PubMed ID: 16211531
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of intraperitoneal cefepime in automated peritoneal dialysis.
Elwell RJ; Frye RF; Bailie GR
Perit Dial Int; 2005; 25(4):380-6. PubMed ID: 16022096
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of intraperitoneal fluconazole during continuous cycling peritoneal dialysis.
Dahl NV; Foote EF; Searson KM; Fein JL; Kapoian T; Steward CA; Sherman RA
Ann Pharmacother; 1998 Dec; 32(12):1284-9. PubMed ID: 9876807
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of intravenous and intraperitoneal ceftazidime in chronic ambulatory peritoneal dialysis.
Demotes-Mainard F; Vinçon G; Ragnaud JM; Morlat P; Bannwarth B; Dangoumau J
J Clin Pharmacol; 1993 May; 33(5):475-9. PubMed ID: 8331207
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of ceftazidime in CAPD-related peritonitis.
Booranalertpaisarn V; Eiam-Ong S; Wittayalertpanya S; Kanjanabutr T; Na Ayudhya DP
Perit Dial Int; 2003; 23(6):574-9. PubMed ID: 14703199
[TBL] [Abstract][Full Text] [Related]
12. Absorption and clearance of ceftazidime during CAPD.
Plant WD; Martin U; Barron W; Scouse PK; Winney RJ; Prescott LF
Perit Dial Int; 1995; 15(8):378-82. PubMed ID: 8785241
[No Abstract] [Full Text] [Related]
13. Pharmacokinetics of once-daily IP gentamicin in CAPD patients.
Low CL; Bailie GR; Evans A; Eisele G; Venezia RA
Perit Dial Int; 1996; 16(4):379-84. PubMed ID: 8863331
[TBL] [Abstract][Full Text] [Related]
14. Intraperitoneal cefazolin and ceftazidime during short-dwell exchange in peritoneal dialysis patients with peritonitis.
Triyawatanyu P; Chariyavilaskul P; Phaisal W; Peerapornratana S; Kanjanabuch T; Praditpornsilpa K; Katavetin P
Perit Dial Int; 2020 Mar; 40(2):179-184. PubMed ID: 32063189
[TBL] [Abstract][Full Text] [Related]
15. Disposition and bioavailability of ceftazidime after intraperitoneal administration in patients receiving continuous ambulatory peritoneal dialysis.
Stea S; Bachelor T; Cooper M; de Souza P; Koenig K; Bolton WK
J Am Soc Nephrol; 1996 Nov; 7(11):2399-402. PubMed ID: 8959631
[TBL] [Abstract][Full Text] [Related]
16. Cefazolin plus netilmicin versus cefazolin plus ceftazidime for treating CAPD peritonitis: effect on residual renal function.
Lui SL; Cheng SW; Ng F; Ng SY; Wan KM; Yip T; Tse KC; Lam MF; Lai KN; Lo WK
Kidney Int; 2005 Nov; 68(5):2375-80. PubMed ID: 16221243
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of ceftazidime in serum and peritoneal exudate during continuous versus intermittent administration to patients with severe intra-abdominal infections.
Buijk SL; Gyssens IC; Mouton JW; Van Vliet A; Verbrugh HA; Bruining HA
J Antimicrob Chemother; 2002 Jan; 49(1):121-8. PubMed ID: 11751775
[TBL] [Abstract][Full Text] [Related]
18. Intermittent intraperitoneal ceftazidime dosing in end-stage renal disease.
Dumler F; Gottschling L; Umstead G; Wilson JM
ASAIO J; 1998; 44(5):M411-4. PubMed ID: 9804462
[TBL] [Abstract][Full Text] [Related]
19. [Treatment of peritonitis under continuous ambulatory peritoneal dialysis using intraperitoneal ceftazidime].
Ragnaud JM; Dupon M; Morlat P; Bezian MC; Wone C
Pathol Biol (Paris); 1989 Jun; 37(5 Pt 2):681-4. PubMed ID: 2677930
[TBL] [Abstract][Full Text] [Related]
20. The effect of peritonitis on the transperitoneal transport of cefuroxime in patients on CAPD treatment.
Dahl K; Walstad RA; Widerøe TE
Nephrol Dial Transplant; 1990; 5(4):275-81. PubMed ID: 2113224
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
